翔宇醫療(688626.SH)：公司豐富的產品結構能夠滿足大單對產品多樣性的需求
格隆匯5月9日丨有投資者向翔宇醫療(688626.SH)提問：公司在大單方面的競爭優勢？公司是行業內率先推出全院康復一體化解決方案的企業，請問目前推進的情況？
翔宇醫療回覆：一是公司豐富的產品結構，能夠滿足大單對產品多樣性的需求。公司自有產品包括康復評定設備、康復訓練設備、康復理療設備、康復輔具、康復護理設備5大門類，已形成20大系列、500多種自有產品的豐富產品結構，在康復醫療器械領域擁有相對完整的產品體系。同時，設備之間實現了互聯互通，可與醫院HIS管理系統和信息管理軟件實現標準化對接，為客户打造智慧化的康復醫療空間。設備在色彩搭配、空間佈局、網絡互聯組合等空間裝備一體化方面的優勢，不是單個或者少數幾款設備能夠實現的。
二是公司具備提供各類康復解決方案的服務能力。公司根據國家衞健委對各種臨牀病症治療的要求，結合疾病與專科治療需求，研製相對應疾病治療的新產品，補充臨牀治療缺失的相應治療手段，形成了疼痛康復解決方案、神經康復解決方案、術後康復解決方案等30多項專科專病的解決方案。除“全科”解決方案外，公司還能為“全院”、“全域”提供全院臨牀康復一體化整體解決方案、（市縣鄉）區域康養一體化整體解決方案，為大單提供方案支撐。
三是公司能夠為大單項目提供綜合的服務保障。公司完善的臨牀講師團隊、宣傳團隊、會議團隊、售後團隊和運營團隊，作為大單項目的後期保障，能夠為項目提供全系列的服務，助力醫院康復醫療服務能力提升。
近年來，面對國家藥佔比的控制和耗材零加成，康復這種非藥物療法，靠服務能力和技術提升來增加醫院收入，受到醫院重點關注，全院臨牀康復一體化建設、康復醫療服務能力建設，成為國家政策落地、醫院收入提升、患者有效康復的一個重要抓手。公司全院臨牀康復一體化項目建設的知名度逐漸提升，建設的大型項目也逐步增多。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
